Antimicrobial dosing in children
Before you prescribe or administer antimicrobials make sure you read the infection management guideline for your patient’s condition. You also need to:
- check if the antimicrobial is appropriate for the indication
- check the formulary and restriction of the antimicrobial
- contact the prescriber to get approval if the antimicrobial is restricted or reserved for use
- document the prescription in ieMR or Metavision
- set a review date for your patient’s treatment.
Children's Health Queensland staff
If further discussion about the appropriateness of antimicrobial treatment is needed follow the antimicrobial stewardship escalation process on the intranet.
You can also access the following guidelines for paediatric dosing and administration information.
- Australian Medical Handbook (AMH) children’s dosing companion
- The Royal Children’s Hospital Melbourne online paediatric injectable guidelines
Dosing recommendations
Recommendations link to the dosage information in our guidelines. They are based on your patient’s age, risk factors and type of infection. Recommendations are only for paediatric patients with normal liver and kidney (renal) function. If your patient has an illness affecting their liver or kidneys, speak to an infectious disease specialist or pharmacist before prescribing antimicrobials.
Antimicrobial name and route of administration | Paediatric dosing recommendation by indication or age |
---|---|
Aciclovir (IV) | Neonatal dosing on the Australasian Neonatal Medicines Formulary website |
Aciclovir (IV) | HSV encephalitis infants over 2 months old and children [PDF 628.53 KB] |
Aciclovir (oral) | Aciclovir monograph – paediatric on the Perth Children's Hospital website |
Albendazole | |
Amikacin (IV) | Intravenous aminoglycoside therapy for Amikacin, Gentamicin and Tobramycin [PDF 368.53 KB] |
Amikacin (inhaled or nebulised) | Cystic fibrosis non tuberculous mycobacterium infection [PDF 613.07 KB] |
Amoxicillin and Clavulanic acid (IV) | |
Amoxicillin and Clavulanic acid (IV) | |
Amoxicillin and Clavulanic acid (IV) | |
Amoxicillin and Clavulanic acid (IV) | |
Amoxycillin and Clavulanic acid (Amoxicillin/Clavulanic acid) (oral or enteral) | |
Amoxycillin and Clavulanic acid (Amoxicillin/ Clavulanic acid) (oral or enteral) | |
Amoxycillin and Clavulanic acid (Amoxicillin/ Clavulanic acid) (oral or enteral) | Appendicitis – early intravenous (IV) to oral switch [PDF 628.53 KB] |
Amoxycillin and Clavulanic acid (Amoxicillin/ Clavulanic acid) (oral or enteral) | Animal bites or wounds inflicted by animal – early intravenous (IV) to oral switch [PDF 628.53 KB] – non PICU |
Amoxycillin and Clavulanic acid (Amoxicillin/ Clavulanic acid) (oral or enteral) | |
Amoxycillin (Amoxicillin) (oral or enteral) | |
Amoxycillin (Amoxicillin) (oral or enteral) | Community acquired pneumonia (CAP) oral antibiotics for infants and children more than 1 month old [PDF 628.53 KB] – ED and inpatient wards |
Amoxycillin (Amoxicillin) (oral or enteral) | |
Amoxycillin (Amoxicillin) (oral or enteral) | |
Amoxycillin (Amoxicillin) (oral or enteral) | |
Amoxycillin (Amoxicillin) (oral or enteral) | |
Amoxycillin (Amoxicillin) (oral or enteral) | |
Amoxycillin (Amoxicillin) (oral or enteral) | |
Oral amoxicillin challenge (low risk) | CHQ-GDL-01076 Paediatric antibiotic allergy assessment, testing and de-labelling [PDF 924.33 KB] – contact AMS or ID team for advice |
Amoxycillin (Amoxicillin) (IV) | Neonatal dosing on the Australasian Neonatal Medicines Formulary website |
Amoxycillin (Amoxicillin) (IV) | Appendicitis – complicated, peritonitis or necrotising enterocolitis [PDF 628.53 KB] |
Ampicillin (IV) | Neonatal dosing on the Australasian Neonatal Medicines Formulary website |
Ampicillin (IV) | Community acquired sepsis in infants under 2 months [PDF 563.28 KB] |
Ampicillin (IV) | |
Ampicillin (IV) | Community acquired pneumonia in neonates less than or equal to 1 month old [PDF 628.53 KB] |
Ampicillin (IV) | Urinary tract infection or pyelonephritis in infants and children [PDF 628.53 KB] |
Ampicillin (IV) | Appendicitis – complicated, perforation, appendiceal collection or abscess [PDF 628.53 KB] |
Ampicillin (IV) | |
Ampicillin (IV) | |
Amphotericin B Liposomal (Ambisome) (IV) | |
Amphotericin B Liposomal (Ambisome) (IV) | |
Amphotericin B Liposomal (Ambisome) (IV) | Febrile neutropenia – febrile more than 96 hours [PDF 622.23 KB] |
Anidulafungin (IV) | |
Artemether and Lumefantrine (Riamet) (oral or enteral) | |
Artesunate (SAS) (IV) | Severe or complicated plasmodium falciparum malaria [PDF 286.34 KB] |
Atovaquone and Proguanil (Malarone) (oral or enteral) | |
Azithromycin (IV) | |
Azithromycin (IV) | Pertussis [PDF 563.28 KB] – PICU |
Azithromycin (oral or enteral) | Non CF bronchiectasis – anti-inflammatory for CSLD [PDF 458.54 KB] |
Azithromycin (oral or enteral) | Pertussis [PDF 628.53 KB] – ED and inpatient wards |
Azithromycin (oral or enteral) | Cystic fibrosis anti-inflammatory (chronic lung disease) [PDF 613.07 KB] |
Azithromycin (oral or enteral) | |
Azithromycin (oral or enteral) | Cystic fibrosis non tuberculous mycobacterium infection (NTM) [PDF 613.07 KB] |
Azithromycin (oral) | Acute medical care of paediatric patients who have experienced alleged sexual abuse/assault for Queensland Health staff on the intranet |
Aztreonam lysine (SAS) (inhaled or nebulised) | |
Aztreonam (IV) | |
Aztreonam (IV) | |
Aztreonam (IV) | |
Baracitinib (oral) | CHQ-GDL-63327 – The management of children with COVID-19 [PDF 1147.64 KB] |
Benzathine Benzylpenicillin (Intra-muscular) | Benzathine Benzylpenicillin administration fact sheet (QSAMSP) |
Benzathine Benzylpenicillin Intra-muscular (S19A Brancaster product) | Preparation and Dosing of Long-acting S19A Benzathine Benzylpenicillin BRANCASTER®️ Product |
Benzylpenicillin (IV) | Neonatal dosing on the Australasian Neonatal Medicines Formulary website |
Benzylpenicillin (IV) | |
Benzylpenicillin (IV) | |
Benzylpenicillin (IV) | |
Tixagevimab-Cilgavimab (Evusheld) | CHQ-GDL-63327 – The management of children with COVID-19 [PDF 1147.64 KB] |
Caspofungin (IV) | |
Cefalexin (oral or enteral) | |
Cefalexin (oral or enteral) | Mild cellulitis, peri-orbital cellulitis, impetigo, cervical lymphadenitis [PDF 628.53 KB] |
Cefalexin (oral or enteral) | |
Cefalexin (oral or enteral) | Neonatal dosing on the Australasian Neonatal Medicines Formulary website |
Cefazolin 5% eye drops | |
Cefazolin (IV) | |
Cefazolin (IV) | General surgical antibiotic prophylaxis [PDF 420.24 KB] – refer to guideline for specific surgery recommendations |
Cefazolin (IV) | Bone and joint infections – Osteomyelitis and septic arthritis [PDF 269.79 KB] |
Cefazolin (IV) | |
Cefazolin (IV) | |
Cefazolin (IV) | |
Cefazolin (IV) (ED HITH) | |
Cefazolin (IV) | Neonatal dosing on the Australasian Neonatal Medicines Formulary website |
Cefepime (IV) | |
Cefepime (IV) | Water immersed wound infection [PDF 181.31 KB] – refer to guideline for specific indications |
Cefepime (IV) | |
Cefotaxime (IV) | Neonatal dosing on the Australasian Neonatal Medicines Formulary website |
Cefotaxime (IV) | Community acquired sepsis in infants and children [PDF 628.53 KB] |
Cefotaxime (IV) | |
Cefotaxime (IV) | |
Cefotaxime (IV) | Severe or life threatening pneumonia in infants and children [PDF 563.28 KB] – PICU |
Cefotaxime (IV) | Non CF bronchiectasis pulmonary optimisation [PDF 458.54 KB] |
Cefotaxime (IV) | Salmonella bacteraemia, meningitis or osteomyelitis [PDF 239.91 KB] |
Cefotaxime (IV) | |
Cefotaxime (IV) | |
Cefotaxime (IV) | |
Cefotaxime (IV) | |
Cefotaxime (IV) | |
Cefoxitin (IV) | Abdominal, kasai, biliary surgery antibiotic prophylaxis [PDF 420.24 KB] |
Cefoxitin (IV) | Cystic fibrosis – Non tuberculous mycobacterium infection [PDF 613.07 KB] |
Ceftazidime (IV) | |
Ceftazidime (IV) | |
Ceftazidime (IV) | Febrile neutropenia – delayed type penicillin hypersensitivity [PDF 622.23 KB] |
Ceftazidime – Avibactam (IV) | Ceftazidime with avibactam on the AMH Children's Dosing Companion website |
Ceftazidime intravitreal injection (ophthalmologist administration) | Acute management of open globe injuries – penetrating eye injury [PDF 317.58 KB] |
Ceftaroline (IV) | Ceftaroline on the AMH Children's Dosing Companion website |
Ceftolozane – Tazobactam (IV) | Ceftolozane and tazobactam drug information on the UpToDate website |
Ceftriaxone (IV) | Community acquired sepsis in infants and children [PDF 628.53 KB] |
Ceftriaxone (IV) | |
Ceftriaxone (IV) | Non CF bronchiectasis pulmonary optimisation [PDF 458.54 KB] |
Ceftriaxone (IM) | Ceftriaxone intramuscular dosing information for infants and children on the AMH Children's Dosing Companion website |
Ceftriaxone (IM administration guidance) | Ceftriaxone intramuscular dose preparation and administration – paediatric injectable guidelines on the Royal Children's Hospital Melbourne website |
Ceftriaxone (IM administration guidance) | Guidelines for maximal amounts of solutions to be injected into muscle tissue for Queensland Health staff on the intranet |
Ceftriaxone (IV) | |
Ceftriaxone (IV) | Salmonella bacteraemia, meningitis or osteomyelitis [PDF 239.91 KB] |
Ceftriaxone IV (ED HITH) | |
Ceftriaxone (IV or IM) | Acute medical care of paediatric patients who have experienced alleged sexual abuse/assault for Queensland Health staff on the intranet |
Cefuroxime (oral or enteral) | |
Cefazolin intracameral injection (ophthalmologist administration) | Acute management of open globe injuries – penetrating eye injury [PDF 317.58 KB] |
Cefazolin intravitreal injection (ophthalmologist administration) | |
Cidofovir (IV) | Cidofovir monograph – paediatric on the Perth Children's Hospital website |
Ciprofloxacin (IV) | |
Ciprofloxacin (IV) | Water immersed wound infections [PDF 181.31 KB] – refer to guideline for specific indications |
Ciprofloxacin (oral or enteral) | |
Ciprofloxacin (oral or enteral) | |
Ciprofloxacin (oral or enteral) | Neisseria meningitidis post exposure prophylaxis [PDF 628.53 KB] |
Ciprofloxacin (oral or enteral) | Pseudomonas aeruginosa – osteomyelitis, bone or joint infection [PDF 269.79 KB] |
Ciprofloxacin ear drops | |
Ciprofloxacin or hydrocortisone ear drops | |
Clarithromycin (oral or enteral) | Cystic fibrosis non tuberculous mycobacterium (NTM) [PDF 613.07 KB] |
Clindamycin (IV) | Neonatal dosing on the Australasian Neonatal Medicines Formulary website |
Clindamycin (oral or enteral) | |
Clindamycin (oral or enteral) | |
Clindamycin (oral or enteral) | |
Clofazimine (oral) (SAS) | Cystic fibrosis non tuberculous mycobacterium (NTM) [PDF 613.07 KB] |
Colistin (IV) | |
Colistin (nebulised) | |
COVID-19 therapies drug interactions | COVID-19 interactions checker on the University of Liverpool website |
Daptomycin (IV) | Daptomycin on the AMH Children's Dosing Companion website |
Doxycycline (oral) | |
Doxycycline (oral) | |
Doxycycline (oral) | Water immersed wound infection [PDF 181.31 KB] – refer to guideline for specific indications |
Doxycycline (oral) | |
Ethambutol (oral) | Cystic fibrosis non tuberculous mycobacterium (NTM) [PDF 613.07 KB] |
Ethambutol (oral) | Tuberculosis on the Queensland Health website |
Fidaxomicin (oral or enteral) | Clostridium (clostridioides) difficile infection [PDF 326.75 KB] |
Flucloxacillin (oral or enteral) | |
Flucloxacillin (oral or enteral) | Mild cellulitis, peri-orbital cellulitis, impetigo and cervical lymphadenitis [PDF 628.53 KB] |
Flucloxacillin (oral or enteral) | |
Flucloxacillin (IV) | Neonatal dosing on the Australasian Neonatal Medicines Formulary website |
Flucloxacillin (IV) | |
Flucloxacillin (IV) | Water immersed wound infection [PDF 181.31 KB] – refer to guideline for specific indications |
Flucloxacillin (IV) | |
Flucloxacillin (IV) | |
Fluconazole (IV) | |
Fluconazole (oral or enteral) | |
Flucytosine (SAS) (oral or enteral) | |
Foscarnet (IV) | Foscarnet monograph – paediatric on the Perth Children's Hospital website |
Fosfomycin (oral) | Fosfomycin monograph – paediatric on the Perth Children's Hospital website |
Fusidic acid – sodium fusidate oral | |
Ganciclovir (IV) | |
Gentamicin antibiotic lock (CVAD) | Antibiotic lock therapy for catheter related blood stream infections [PDF 275.66 KB] |
Gentamicin (IV) | |
Gentamicin (IV) | Intravenous aminoglycoside therapy – Amikacin, Gentamicin and Tobramycin [PDF 368.53 KB] |
Gentamicin IV (ED HITH) | |
Gentamicin (IV) | General surgical antibiotic prophylaxis in patients with penicillin or cephalosporin hypersensitivity [PDF 420.24 KB] – refer to guideline for specific surgery recommendations |
Gentamicin eye drops | |
G6PD deficiency medication safety | G6PD deficiency medicines safety on the UpToDate website |
Hepatitis B immunoglobulin | |
Hospital In The Home (HITH) IV antimicrobials | HITH guide for Queensland Health staff on the intranet |
Human rabies immunoglobulin | |
HIV drug interactions | HIV drug interactions on the University of Liverpool website |
Imipenem and cilastatin (IV) | Cystic fibrosis non tuberculous mycobacterium (NTM) [PDF 613.07 KB] |
Isoniazid (oral or enteral) | Tuberculosis on the Queensland Health website |
Itraconazole (oral or enteral) | |
Itraconazole (oral or enteral) | Cystic fibrosis allergic bronchopulmonary aspergillosis (ABPA) [PDF 613.07 KB] |
Ivermectin (oral or enteral) | Strongyloides and immunosuppressed children – Screening, management and prophylaxis for Queensland Health staff on the intranet |
Lamivudine (oral or enteral) | |
Lamivudine (oral) | |
Lincomycin (IV) | Community acquired pneumonia with empyema [PDF 628.53 KB] – non PICU |
Lincomycin (IV) | General surgical antibiotic prophylaxis in patients with penicillin or cephalosporin hypersensitivity [PDF 420.24 KB] – refer to guideline for specific surgery recommendations) |
Lincomycin (IV) | Water immersed wound infection [PDF 181.31 KB] – refer to guideline for specific indications |
Lincomycin (IV) | |
Lincomycin (IV) | Severe or life threatening pneumonia in infants and children [PDF 563.28 KB] – PICU |
Lincomycin (IV) | |
Lincomycin (IV) | |
Linezolid (oral and IV) | Cystic fibrosis non tuberculous mycobacterium infection (NTM) [PDF 613.07 KB] |
Lopinavir or Ritonavir (Kaletra) (oral) | |
Measles – post exposure prophylaxis | Immunoglobulin: NHIg, HBIg, TIg and Zig – Passive immunisation for Queensland Health staff on the intranet |
Mebendazole (oral) | |
Meropenem (IV) | Febrile neutropenia in patients with anaphylaxis to beta lactams [PDF 622.23 KB] |
Meropenem (IV) | |
Meropenem (IV) | |
Meropenem (IV) | |
Meropenem (IV) | External wound or inoculation with suspected necrotising fasciitis [PDF 628.53 KB] – non PICU |
Meropenem (IV) | Neonatal dosing on the Australasian Neonatal Medicines Formulary website |
Metronidazole (IV) | General surgical antibiotic prophylaxis in patients with penicillin or cephalosporin hypersensitivity [PDF 420.24 KB] – refer to guideline for specific surgery recommendations |
Metronidazole (IV) | Neonatal dosing on the Australasian Neonatal Medicines Formulary website |
Metronidazole (IV) | Appendicitis (complicated), peritonitis or NEC [PDF 628.53 KB] |
Metronidazole (IV) | |
Metronidazole (oral) | Clostridium difficile infection – mild or moderate [PDF 326.75 KB] |
Metronidazole (oral) | |
Metronidazole (IV) | |
Metronidazole (IV) | Water immersed wound infection [PDF 181.31 KB] – refer to guideline for specific indications |
Metronidazole (IV) | |
Micafungin (IV) | |
Minocycline (oral) | |
Moxifloxacin (oral and IV) | |
Mupirocin (intranasal ointment) | Eradication of S. aureus nasal colonisation in cardiac surgery patients [PDF 420.24 KB] |
Natamycin eye drops (SAS) | |
Nevirapine (oral or enteral) | |
Nirvesimab (IMI) | The Queensland Paediatric Respiratory Syncytial Virus Prevention Program - Nirsevimab |
Ofloxacin eye drops | |
Oseltamivir (oral) | CDC recommended dosage and duration of treatment or chemoprophylaxis for influenza antiviral medications on the CDC website |
Palivizumab (IM) | RSV prophylaxis for high risk patient groups for Queensland Health staff on the intranet |
Phenoxymethylpenicillin (oral) | Tonsillitis [PDF 628.53 KB] – non PICU |
Piperacillin and Tazobactam (IV) | |
Piperacillin and Tazobactam (IV) | |
Piperacillin and Tazobactam (IV) | |
Piperacillin and Tazobactam (IV) | |
Piperacillin and Tazobactam (IV) | Non CF bronchiectasis pulmonary optimisation [PDF 458.54 KB] |
Piperacillin and Tazobactam (IV) | |
Piperacillin and Tazobactam (IV) | Compound fractures – Open fractures severe tissue damage or evidence of infection [PDF 628.53 KB] |
Porphyria medication safety | Drug database – on the American Porphyria Foundation website |
Porphyria medication safety | Drug safety – on the British Porphyria Association website |
Posaconazole (IV) | |
Posaconazole (oral) | |
Primaquine (oral) | Malaria plasmodium ovale and plasmodium vivax [PDF 286.34 KB] Note: There are different dosing recommendations, make sure you check carefully before prescribing |
Pyrazinamide (oral) (SAS) | Tuberculosis on the Queensland Health website |
Quinine sulfate (oral) (SAS) | |
Rabies vaccine | |
Raltegravir (oral or enteral) | |
Raltegravir (oral) | |
Remdesivir (IV) | CHQ-GDL-63327 – The management of children with COVID-19 [PDF 1147.64 KB] |
Rifampicin (oral or enteral) | |
Rifampicin (oral or enteral) | |
Rifampicin (oral or enteral) | Tuberculosis on the Queensland Health website |
Sarilumab (IV) | CHQ-GDL-63327 – The management of children with COVID-19 |
Taurolidine/citrate antiseptic lock (Taurolock) | Use of taurolidine/citrate lock solution in the prevention of central venous catheter related bacteraemia for Queensland Health staff on the intranet |
Teicoplanin (IV) | |
Teicoplanin (IV) | CHQ-PROC-03455 – Management of compromised Central Venous Access Device (CVAD) [PDF 304.16 KB] |
Teicoplanin (IV) | |
Truvada – Tenofovir 300 mg or Emtricitabine 200 mg (oral) | Paediatric guideline post-exposure prophylaxis for HIV for Queensland Health staff on the intranet |
Terbinafine (oral or enteral) | |
Tetanus containing vaccine | |
Tetanus immunoglobulin | |
Tigecycline (IV) | Cystic fibrosis non tuberculous mycobacterium infection (NTM) [PDF 613.07 KB] |
Tobramycin (inhaled TOBI podhaler) | |
Tobramycin (IV) |
|
Tobramycin (IV) | |
Tobramycin (TOBI nebulised) | |
Tobramycin (TOBI nebulised) | |
Trimethoprim or Sulfamethoxazole (oral or enteral) | Water immersed wound infection [PDF 181.31 KB] – refer to guideline for specific indications |
Trimethoprim or Sulfamethoxazole (IV) | |
Trimethoprim or Sulfamethoxazole (IV) | nmMRSA osteomyelitis, bone or joint infection [PDF 269.79 KB] |
Trimethoprim or Sulfamethoxazole (oral or enteral) | nmMRSA osteomyelitis, bone or joint infection [PDF 269.79 KB] |
Trimethoprim or Sulfamethoxazole (oral or enteral) | Cystic fibrosis MRSA with severe infection – outpatients [PDF 613.07 KB] |
Trimethoprim or Sulfamethoxazole (oral or enteral) | |
Trimethoprim or Sulfamethoxazole (oral) | |
Valaciclovir (oral or enteral) | Valaciclovir monograph – paediatric on the Perth Children's Hospital website |
ValGANciclovir (oral) | Renal transplant CMV prophylaxis for Queensland Health staff on the intranet |
ValGANciclovir (oral) | Liver transplant CMV prophylaxis for Queensland Health staff on the intranet |
ValGANciclovir (oral) | |
Vancomycin antibiotic lock (CVAD) | Antibiotic lock therapy for catheter related blood stream infections [PDF 275.66 KB] |
Vancomycin (IV) | |
Vancomycin (IV) | Neonatal dosing on the Australasian Neonatal Medicines Formulary website |
Vancomycin (oral or enteral) (suspension – SAS) | Clostridium difficile infection – moderate or severe [PDF 326.75 KB] Primary sclerosing cholangitis in ulcerative colitis for Queensland Health staff on the intranet |
Vancomycin intravitreal injection (ophthalmologist administration) | |
Vancomycin intracameral injection (ophthalmologist administration) | |
Varicella Zoster Immunoglobulin (ZIG) | Immunoglobulin: NHIg, HBIg, TIg and Zig – Passive Immunisation for Queensland Health staff on the intranet |
Voriconazole eyedrops | |
Voriconazole (IV) | |
Voriconazole (oral or enteral) | |
Voriconazole Intravitreal injection (ophthalmologist administration) | |
Zidovudine (IV) (SAS) | |
Zidovudine (oral) | |
Lamivudine/Zidovudine – Combivir (oral) | |
Glecaprevir or pibrentasvir (Maviret) (oral) | Hepatitis C virus (HCV) in children: Australian commentary on AASLD-IDSA guidance on the ASHM website |
Sofosbuvir or velpatasvir (Epclusa) (oral) | Hepatitis C virus (HCV) in children: Australian commentary on AASLD-IDSA guidance on the ASHM website |
Ledipasvir or Sofosbuvir (Harvoni) (oral) | Hepatitis C virus (HCV) in Children: Australian Commentary on AASLD-IDSA Guidance on the ASHM website |
Hepatitis C Direct acting antiviral drug interactions | HEP drug interactions on the University of Liverpool website |
Nirmatrelvir or ritonavir (Paxlovid) oral | CHQ-GDL-63327 – The management of children with COVID-19 for Queensland Health staff on the intranet |
Molnupiravir (oral) | CHQ-GDL-63327 – The management of children with COVID-19 for Queensland Health staff on the intranet |
Aciclovir IV | CHQ-GDL-02219 Antiviral Prophylaxis and Treatment in Haematopoietic Stem Cell Transplant and Immunocompromised children |
Valaciclovir oral/enteral | CHQ-GDL-02219 Antiviral Prophylaxis and Treatment in Haematopoietic Stem Cell Transplant and Immunocompromised children |
Ganciclovir IV | CHQ-GDL-02219 Antiviral Prophylaxis and Treatment in Haematopoietic Stem Cell Transplant and Immunocompromised children |
ValGANciclovir oral/enteral | CHQ-GDL-02219 Antiviral Prophylaxis and Treatment in Haematopoietic Stem Cell Transplant and Immunocompromised children |
Cidofovir IV | CHQ-GDL-02219 Antiviral Prophylaxis and Treatment in Haematopoietic Stem Cell Transplant and Immunocompromised children |
Foscarnet IV | CHQ-GDL-02219 Antiviral Prophylaxis and Treatment in Haematopoietic Stem Cell Transplant and Immunocompromised children |
Letermovir IV/oral/enteral | CHQ-GDL-02219 Antiviral Prophylaxis and Treatment in Haematopoietic Stem Cell Transplant and Immunocompromised children |
Maribavir oral/enteral | CHQ-GDL-02219 Antiviral Prophylaxis and Treatment in Haematopoietic Stem Cell Transplant and Immunocompromised children |